T6A Biomarker for Detection of Bacterial Infection in Newborn Infants
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorSalzburger Landeskliniken
About this trial
This study aims to assess the efficacy of a new biomarker, N6-threonylcarbamoyladenosine (t6A), for the early diagnosis of Early-Onset Sepsis (EOS) in newborns.
Eligibility criteria
Qualifiers
Newborn infants who require blood testing for screening for bacterial infection OR treating physician suspects bacterial infection in newborn infant
Signed informed consent form
Disqualifiers
Refusal to participate in study or not providing written informed consent by caregivers/parents
Antibiotic treatment of any kind.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
210 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Salzburger Landeskliniken
Lead sponsor
Wroclaw Medical University
Collaborator
Source ClinicalTrials.gov